Rankings / Hormones & Endocrine
Other aromatase inhibitors (letrozole / exemestane / formestane / arimistane)
Hormones & Endocrine · Aromatase inhibitor
Tier C+
Bottom line
Read Off Label grades Other aromatase inhibitors (letrozole / exemestane / formestane / arimistane) as C+ (5.5/10) based on moderate evidence, med benefit magnitude, and a med-risk safety profile.
WADA coverage: 2-Androstenol, 2-Androstenone, alpha-naphthoflavone/7,8-benzoflavone, 3-Androstenol, 3-Androstenone, 6-OXO, aminoglutethimide, anastrozole, androstatrienedione/ATD, arimistane, exemestane, formestane, letrozole and testolactone.
Studied, labeled, or reported-use context: Clinical oncology dosing varies; no healthy optimization dose — Rx for oncology/endocrine indications or gray-market supplement/research chemical; WADA S4 prohibited; not individualized guidance.
What the evidence says
WADA coverage: 2-Androstenol, 2-Androstenone, alpha-naphthoflavone/7,8-benzoflavone, 3-Androstenol, 3-Androstenone, 6-OXO, aminoglutethimide, anastrozole, androstatrienedione/ATD, arimistane, exemestane, formestane, letrozole and testolactone. Anastrozole remains its own row; this row covers the remaining WADA aromatase-inhibitor class.
Mechanism
Aromatase inhibitors lower estrogen synthesis and are used medically in estrogen-receptor-positive breast cancer; biohacker/bodybuilding use aims to alter testosterone:estradiol balance.
Studied, labeled, or reported dose & route
Clinical oncology dosing varies; no healthy optimization dose
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Other aromatase inhibitors (letrozole / exemestane / formestane / arimistane)'s effects?
- Read Off Label rates the evidence for Other aromatase inhibitors (letrozole / exemestane / formestane / arimistane) as Moderate and the benefit magnitude as med, producing an overall grade of C+ (5.5/10). WADA coverage: 2-Androstenol, 2-Androstenone, alpha-naphthoflavone/7,8-benzoflavone, 3-Androstenol, 3-Androstenone, 6-OXO, aminoglutethimide, anastrozole, androstatrienedione/ATD, arimistane, exemestane, formestane, letrozole and testolactone.
- What safety findings are reported for Other aromatase inhibitors (letrozole / exemestane / formestane / arimistane)?
- Other aromatase inhibitors (letrozole / exemestane / formestane / arimistane) has a med risk profile in the database. Med (low estradiol symptoms, bone/lipid effects, joint pain, fertility and mood effects) Legal status: Rx for oncology/endocrine indications or gray-market supplement/research chemical; WADA S4 prohibited.
- What doses or routes are reported for Other aromatase inhibitors (letrozole / exemestane / formestane / arimistane)?
- Clinical oncology dosing varies; no healthy optimization dose This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Other aromatase inhibitors (letrozole / exemestane / formestane / arimistane) work?
- Aromatase inhibitors lower estrogen synthesis and are used medically in estrogen-receptor-positive breast cancer; biohacker/bodybuilding use aims to alter testosterone:estradiol balance.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.